Monitoring Breast Cancer Metastasis And Treatment Efficacy


To develop an effective yet low-cost blood test capable of detecting signs of breast cancer recurrence early to improve survival

Anticipated Impact: 

More effective and targeted treatment for individuals with metastatic breast cancer


In Washington State, breast cancer is the most frequently diagnosed cancer and the second leading cause of cancer death among women. An effective yet low-cost blood test capable of detecting signs of breast-cancer recurrence early will improve survival. Equally important, such a blood test may be used to evaluate periodically the effectiveness of a treatment regimen, granting patients precious opportunities to seek alternate treatment before more time or money is spent: in addition to subjecting patients to unnecessary devastating side effects. Ineffective chemotherapy, for example, can cost up to thousands per month, which is a significant burden on the healthcare system.

This project will develop a biochip for performing such a blood test and conduct a study to evaluate the performance of the biochip. Such a blood test will become an important assessment tool to pharmaceuticals for evaluating patients' response to a cancer drug during treatment, and it will complement other cancer monitoring methods, such as radiological imaging techniques (e.g. CT or MRI scans). This project, when successfully validated with clinical samples, will give rise to powerful tools to facilitate cancer prognosis and diagnosis as well as the decision when to start or stop treatment.

See also:

Breast Cancer Prognosis, Therapies

Grant Update

Principal Investigator:
Daniel Chiu
Grantee Organization:
University of Washington
Grant Title:
Monitoring Breast-Cancer Metastasis and Treatment Efficacy
Grant Cohort and Year:
2007 Beneficial Applications of Technology in Health Care: Improving Health-Care Quality and Cost Effectiveness (01)
Grant Period:
01/01/2008 - 12/31/2010 (Completed)
Grant Amount:
With the completion of LSDF project, we have successfully developed and validated our biochip-based platform for isolating circulating tumor cells directly from the blood of breast cancer patients. The performance of the biochip platform has compared favorably to existing methods available. Important clinical results will be published in 2011. We are now transitioning to commercialization of the technology and are in progress of seeking suitable investment and manufacturing partners.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
11, 34, 36, 37, 43, 46

Health Impacts

Breast Cancer Prognosis, Therapies